Zenas Biopharma (NASDAQ:ZBIO) Receives “Buy” Rating from HC Wainwright

Zenas Biopharma (NASDAQ:ZBIO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 186.53% from the company’s current price.

A number of other equities research analysts also recently issued reports on ZBIO. Wedbush reiterated an “outperform” rating and set a $35.00 price objective on shares of Zenas Biopharma in a research note on Thursday. Guggenheim reissued a “buy” rating and issued a $45.00 target price on shares of Zenas Biopharma in a report on Wednesday, March 12th.

Zenas Biopharma Price Performance

Shares of Zenas Biopharma stock opened at $10.47 on Friday. The firm has a market capitalization of $438.00 million and a P/E ratio of -2.95. Zenas Biopharma has a 12-month low of $5.83 and a 12-month high of $26.25. The business’s 50-day moving average price is $8.92.

Zenas Biopharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $5.00 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ZBIO. New York State Common Retirement Fund bought a new position in shares of Zenas Biopharma in the first quarter worth about $49,000. Nuveen LLC bought a new position in Zenas Biopharma in the 1st quarter valued at approximately $250,000. Finally, Jefferies Financial Group Inc. acquired a new stake in Zenas Biopharma during the 1st quarter worth approximately $348,000.

Zenas Biopharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.